Highline Wealth Partners LLC Zentalis Pharmaceuticals, Inc. Transaction History
Highline Wealth Partners LLC
- $355 Billion
- Q4 2025
A detailed history of Highline Wealth Partners LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Highline Wealth Partners LLC holds 5,000 shares of ZNTL stock, worth $6,650. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,000
Previous 12,000
58.33%
Holding current value
$6,650
Previous $18.1 Million
62.75%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ZNTL
# of Institutions
106Shares Held
57.9MCall Options Held
0Put Options Held
43.4K-
Matrix Capital Management Company, LP Waltham, MA14MShares$18.6 Million33.01% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.41 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.9MShares$3.86 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.85MShares$3.78 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.33MShares$3.09 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $75.8M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...